India moves to cap trade margins on non-scheduled cancer drugs at 30% of MRP

The Economic Times reports that India’s government has decided to cap trade margins on non-scheduled cancer drugs at 30% of MRP. An expert committee is expected to recommend which medicines the cap will cover. The National Pharmaceutical Pricing Authority estimates the move could cut prices by roughly 20–70% and save patients around ₹2,500 crore a year. An affordability group argues that a 2019 margin cap did little to make treatment affordable.